News & Industry Updates

Other Oct 12, 2021

ReAlta to Participate in Needham Biotech Forum

Norfolk, VA, September 22, 2021 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer and...

Read More
Other Sep 22, 2021

ReAlta to Participate in Oppenheimer Healthcare Summit

Norfolk, VA, September 22, 2021 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer and John...

Read More
Press Releases Jun 08, 2021

ReAlta Life Sciences Receives $3.2 Million Grant from Virginia Catalyst to Accelerate...

RLS-0071 is in development for treatment of Acute Lung Injury (ALI) and Hypoxic Ischemic Encephalopathy (HIE) Norfolk, VA, June 8,...

Read More
Other Jun 07, 2021

Norfolk startup studying COVID-19 treatment completes $20 million funding round

The Virginian Pilot A Norfolk biotech startup researching treatments for a serious side effect of COVID-19 recently received another funding...

Read More
Press Releases May 18, 2021

ReAlta Life Sciences Expands Phase 1 Clinical Trial of RLS-0071 to Include...

RLS-0071 is in development for treatment of Acute Lung Injury (ALI) and Hypoxic Ischemic Encephalopathy (HIE) Norfolk, VA, May...

Read More
Press Releases Apr 28, 2021

ReAlta Life Sciences Closes $20 Million Series A3 Financing to Advance Multiple...

Proceeds to Fund Programs Addressing Acute Lung Injury (ALI) and Hypoxic Ischemic Encephalopathy (HIE) Norfolk, VA, April 28, 2021 —...

Read More
Press Releases Apr 09, 2021

ReAlta Life Sciences to Participate in the 20th Annual Needham Virtual Healthcare...

Norfolk, VA, April 9, 2021 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive...

Read More
Press Releases Feb 16, 2021

ReAlta Life Sciences Doses First Subject In Phase 1 Healthy Volunteers Study...

Norfolk, VA, February 16, 2021 – ReAlta Life Sciences, Inc. (“ReAlta”), a company addressing life-threatening diseases through harnessing the power...

Read More
Press Releases Dec 03, 2020

ReAlta Life Sciences Announces EMA Orphan Drug Designation for RLS-0071 For The...

Norfolk, VA, December 3, 2020 — ReAlta Life Sciences, Inc., today announced that the European Medicines Agency (EMA) has granted Orphan...

Read More